Clinical trial NCT01561079: Fetal and Infant Effects of Maternal Buprenorphine Treatment
Official title: Fetal and Infant Effects of Maternal Buprenorphine Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Neonatal Abstinence Syndrome
Keywords: Buprenorphine
Methadone
Fetal neurobehavior
Infant neurobehavior
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2012-03-22
Enrollment: 127
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This research will track the longitudinal neurobehavioral development of the buprenorphine-exposed fetus across gestation through 1 month of age in an effort to determine the safety of this medication for use during gestation, the relationship between maternal physiologic changes due to buprenorphine administration and newborn functioning, and to determine potential fetal neurobehavioral markers that may predict Neonatal Abstinence Syndrome expression and infant neurobehavioral outcome. Comparisons to results from a similar project in methadone-exposed pregnancies will be made. This proposal seeks to advance the way the investigators inform the treatment of the opioid dependent woman during pregnancy and her infant after birth.

Detailed description: There is an increase in the prevalence of illicit opiate use among women of childbearing age in many countries today. Methadone is the treatment of choice for opioid dependency during pregnancy in the US because it markedly diminishes withdrawal symptoms and craving and blocks opioid effects, however, in utero exposure results in significant depression of fetal neurobehaviors such as fetal heart rate and heart rate variability and fetal motor activity, and significant neonatal abstinence syndrome (NAS) in the majority of exposed infants. Since its approval in 2002, the prescription of buprenorphine for opioid dependence has increased dramatically but, as with methadone, this mediation is not approved for use during pregnancy. Currently, women treated with buprenorphine prior to pregnancy are transitioned to methadone treatment due to a lack of information regarding the effects of buprenorphine on the developing fetus and infant. Pilot work by this research team suggests that buprenorphine- as compared to methadone-exposed fetuses display more optimal neurobehavioral functioning in the second and third trimesters of pregnancy. Although these results are encouraging, there is a critical need to explore fully the effects of this medication on the fetus and infant to adequately advise care providers and patients regarding its use. This is particularly true given the imminent publication of a pivotal study comparing buprenorphine to methadone treatment during pregnancy which has suggested the optimality of buprenorphine for the treatment of opioid dependence during pregnancy, and is likely to result in increasing numbers of women being treated with off-label buprenorphine during pregnancy. This proposal seeks to explore the effect of buprenorphine on maternal physiology and fetal neurobehavioral functioning longitudinally as a measure of the development of the fetal nervous system. Additionally, the neurobehavioral profile and NAS of the buprenorphine-exposed infant up to one month will be delineated in an effort to provide information necessary to provide optimal pharmacologic and non-pharmacologic treatment of NAS. Furthermore, this group has previously explored similar parameters in methadone-exposed fetuses and infants, and results of this study can be compared to those historical data. These parameters will advance our understanding of the way the investigators view and implement the future pharmacologic treatment of the opiate dependent woman during pregnancy and her infant after birth, and inform clinicians, health insurance companies and regulatory agencies in the provision of optimal care to the opioid dependent pregnant woman and her offspring before and after birth.

Eligibility criteria: Inclusion Criteria:

* Current opioid dependence as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-R criteria
* 18-40 years of age with uncomplicated singleton pregnancies
* Accurate gestational age dating verified by ultrasound
* Gestation of less than 34 weeks
* Stabilization on buprenorphine for one week prior to study procedures

Exclusion Criteria:

* Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery (i.e. incompetent cervix)
* Evidence of fetal malformation detected by prenatal ultrasound
* Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension.
* Significant maternal psychopathology that would preclude informed consent (i.e. schizophrenia)
* Alcohol dependency per DSM IV R criteria (see ascertainment methods below)
* Women stable on methadone maintenance (defined as more than 3 days of methadone dosing)
* Women entering drug treatment reporting using "street" methadone (for more than 3 days)

Primary outcomes:
measure: Fetal Heart Rate
timeFrame: 24, 28, 32 and 36 weeks of gestation
measure: Fetal Heart Rate Variability
timeFrame: 24, 28, 32 and 36 weeks of gestation
measure: Accelerations of Fetal Heart Rate
timeFrame: 24, 28, 32 36 weeks of gestation
measure: Fetal Movement
timeFrame: 24, 28, 32, 36 weeks of gestation
measure: Fetal Movement - Fetal Heart Rate Coupling
timeFrame: 24, 28, 32, 36 weeks of gestation
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Center for Addiction and Pregnancy
state: Maryland
city: Baltimore
country: United States
facility: Johns Hopkins Bayview Medical Center
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Lauren M Jansson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jansson LM, Dipietro JA, Velez M, Elko A, Williams E, Milio L, O'Grady K, Jones HE. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol. 2011 Mar-Apr;33(2):240-3. doi: 10.1016/j.ntt.2010.09.003. Epub 2010 Sep 22.
citation: Velez ML, McConnell K, Spencer N, Montoya L, Tuten M, Jansson LM. Prenatal buprenorphine exposure and neonatal neurobehavioral functioning. Early Hum Dev. 2018 Feb;117:7-14. doi: 10.1016/j.earlhumdev.2017.11.009. Epub 2017 Dec 7.